Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia

Journal of Clinical Psychiatry

Volumn 73, Issue 5, 2012, Pages 696-702

  Barnett, Paul G ^a,b   Scott, Jennifer Y ^a   Krystal, John H ^c,d   Rosenheck, Robert A ^c,d  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL HEALTH SERVICE; OUTPATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84861807305     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07070     Document Type: Article

References (36)

1. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54(4):508-516. doi:10.176/api.ps.54.4.508 PubMed (Pubitemid 36752981)
2. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419-429. PubMed
3. Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother. 2010;11(14):2301-2317. doi:10.1517/1465656.2010.49125 PubMed
4. Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics. 2005;23(suppl 1):62-74. doi:10.2165/019053-2052301-06 PubMed
5. Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005; 23(suppl 1):75-89. doi:10.2165/019053-2052301-07 PubMed
6. Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005;59(4):385-394. doi:10.1/j.140-1819.205.01390.x PubMed (Pubitemid 41139546)
7. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry suppl. 2009;195(52):S29-S36. doi:10.192/bjp.195.52.s29 PubMed
8. Olivares JM, Rodriguez-Morales A, Diels J, et al; e-STAR Spanish Study Group. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287-296. doi:10.1016/j.eurpsy.208.12.02 PubMed
9. Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf. 2004;13(11):811-816. doi:10.102/pds.978 PubMed (Pubitemid 39496905)
10. Olivares JM, Rodriguez-Martinez A, Burón JA, et al; e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41-53. doi:10.2165/0148365-20806010-04 PubMed
11. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007;116(1):36-46. doi:10.1/j.160-047.206.0980.x PubMed (Pubitemid 46889775)
12. Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand. 2009;120(2):97-101. doi:10.1/j.160-047.209.01352.x PubMed
13. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111-117. doi:10.1016/j.euroneuro.204.07.03 PubMed (Pubitemid 39574406)
14. Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007; 68(8):1218-1225. doi:10.408/JCP.v68n0808 PubMed (Pubitemid 47395624)
15. Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007; 191(2):131-139. doi:10.192/bjp.bp.105.017020 PubMed (Pubitemid 47204533)
16. Macfadden W, Ma YW, Thomas Haskins J, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont). 2010;7(11):23-31. PubMed
17. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367-2377. doi:10.1038/np.2010.1 PubMed
18. Rosenheck RA, Krystal JH, Lew R, et al; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851. doi:10.1056/NEJMoa105987 PubMed
19. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for Axes I and II DSM-IV Disorders - Patient Edition (SCID-I/P). New York, NY: Biometrics Research Institute, New York State Psychiatric Institute; 1966.
20. Barnett PG. An improved set of standards for finding cost for cost-effectiveness analysis. Med Care. 2009;47(suppl 1):S82-S88. doi:10.1097/MLR.0b013e31819e1f3f PubMed
21. Render ML, Nowak J, Hammond EK, et al. Methods for estimating and comparing VA outpatient drug benefits with the private sector. Med Care. 2003;41(suppl):1161-1169. doi:10.1097/01.MLR.068420.29471.F8 PubMed
22. McDonald M, Hertz RP, Lustik MB, et al. Healthcare spending among community-dwelling adults with schizophrenia. Am J Manag Care. 2005; 11(suppl):S242-S247. PubMed (Pubitemid 41361625)
23. Congress of the United States. Congressional Budget Office. Prices for Brand-Name Drugs Under Selected Federal Programs; 2005 June. Available at: http://www.cbo.gov/ftpdocs/64xx/doc6481/06-16-PrescriptDrug.pdf. Accessed December 7, 2011.
24. Smith SL, ed. Medicare RBVS 2009: The Physicians' Guide. Chicago, IL: American Medical Association; 2009.
25. Bureau of Labor Statistics. US Department of Labor. Consumer Price Index. All Urban Consumers (Chained CPI). 2006-2009. Available at: http://www.bls.gov/cpi/data.htm. Accessed September 30, 2010.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
27. Kaplan R, Sieber WJ, Ganiats TG. The Quality of Well-Being Scale: comparison of the interviewer-administered versions with a self-administered questionnaire. Psychol Health. 1997;12(6):783-791. doi:10.1080/087049708406739 (Pubitemid 127538602)
28. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
29. Pyne JM, Sullivan G, Kaplan R, et al. Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med Care. 2003;41(2):208-217. doi:10.1097/01.MLR.0490.72470.D4 PubMed
30. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461-494. doi:10.1016/S0167-6296(01)086-8 PubMed (Pubitemid 32515166)
31. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87(2):329-343. doi:10.1093/biomet/87.2.329
32. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry suppl. 2009;195(52):S20-S28. doi:10.192/bjp.195.52.s20 PubMed
33. Rosenheck RA, Desai R, Steinwachs D, et al. Benchmarking treatment of schizophrenia: a comparison of service delivery by the national government and by state and local providers. J Nerv Ment Dis. 2000; 188(4):209-216. doi:10.1097/05053-2040-03 PubMed (Pubitemid 30210861)
34. Leslie DL, Rosenheck RA. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector. J Ment Health Policy Econ. 2003;6(3):113-121. PubMed (Pubitemid 37408227)
35. Nugent GN, Hendricks A, Nugent LB, et al. Value for taxpayers' dollars: what VA care would cost at medicare prices. Med Care Res Rev. 2004; 61(4):495-508. doi:10.17/10758704269795 PubMed (Pubitemid 39491931)
36. Bruen BK, Miller LM. Changes in Medicaid prescription volume and use in the wake of Medicare Part D implementation. Health Aff (Millwood). 2008;27(1):196-202. doi: (Pubitemid 351198605)